Local Anaesthetic and Steroid in the Ureter (LASTE)
Primary Purpose
Pain, Postoperative, Ureter Stone
Status
Unknown status
Phase
Not Applicable
Locations
Ireland
Study Type
Interventional
Intervention
Levobupivacaine
Dexamethasone Sodium Phosphate
Placebos
Sponsored by
About this trial
This is an interventional prevention trial for Pain, Postoperative focused on measuring ureteroscopy, ureteric stent, intraluminal, local anaesthetic/anesthetic, steroid/glucocorticoid
Eligibility Criteria
Inclusion Criteria:
- Any patient undergoing ureteroscopy for ureteric stone disease
- Able to undergo a general anaesthetic
- At least 18 years old
- Willing and able to complete patient symptom questionnaires
Exclusion Criteria:
- Solitary Kidney
- Renal failure
- Anatomic bladder or ureteral abnormality
- Uncorrected coagulopathy
- Previous cystectomy or urinary diversion
- Neurogenic bladder
- Interstitial cystitis
- Transplanted kidney
- Pregnancy
- Requires an indwelling catheter
- Recurrent urinary tract infections
- Pelvic kidney
- Requires bilateral treatment/stents
- Previous bladder or ureteral reconstructive surgery
- Ureteral perforation during procedure
- Known sensitivity to lidocaine
- Febrile at time of randomization or treatment
- Requires spinal anaesthetic
- Stenting without stone treatment
Sites / Locations
- Adelaide and Meath incorporating National Children's hopsital
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Active Comparator
Active Comparator
Placebo Comparator
Arm Label
Local anaesthetic
Local anaesthetic + steroid
Placebo
Arm Description
Post-ureteroscopy intraluminal injection of alkalinised high concentration levo-bupivicaine in the renal pelvis
Post-ureteroscopy intraluminal injection of 10 mls alkalinised high concentration levo-bupivicaine with l dexamethasone in the renal pelvis
Post-ureteroscopy intraluminal injection of 10 mls normal saline (placebo) in the renal pelvis
Outcomes
Primary Outcome Measures
Pain
Visual Analog Pain Scale (VAS) at least 3 different time points post-ureteroscopy
Secondary Outcome Measures
Postoperative Nausea and Vomiting (PONV)
Length of stay post-op
rehospitalisation rate
Need for analgesia
Full Information
NCT ID
NCT03296189
First Posted
September 8, 2017
Last Updated
January 12, 2018
Sponsor
The Adelaide and Meath Hospital, incorporating The National Children's Hospital
1. Study Identification
Unique Protocol Identification Number
NCT03296189
Brief Title
Local Anaesthetic and Steroid in the Ureter
Acronym
LASTE
Official Title
Intraluminal Ureteric Injection of High Concentration Alkalinised Long-acting Local Anaesthetic and STeroid Post urEteroscopy: A Prospective Double Blinded Randomised Controlled Trial (LASTE Trial)
Study Type
Interventional
2. Study Status
Record Verification Date
January 2018
Overall Recruitment Status
Unknown status
Study Start Date
November 1, 2018 (Anticipated)
Primary Completion Date
December 1, 2019 (Anticipated)
Study Completion Date
December 31, 2019 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
The Adelaide and Meath Hospital, incorporating The National Children's Hospital
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Précis:
Randomised control trial to evaluate safety and efficacy of intraluminal injection of high pH-high concentration of a long-acting local anesthetic and long-acting glucocorticoid in the ureter after ureteroscopy.
Objectives:
To evaluate a novel method to ameliorate post-ureteroscopy pain in all patients (with and without stents)
Endpoints:
Primary endpoint: mean visual analog pain scale (VAS) post-operatively starting at 1 hour, 4 hours, 8 hours, 24 hours and 7 days post-procedure (minimum of 3 VAS scores). VAS pain, ureteral stent symptoms and analgesic requirement will be assessed at different points during this time period.
Secondary endpoint: Postoperative Nausea/Vomiting (PONV), safety of intraluminal injection of high concentration alkalinized local anaesthetic solution by comparing adverse events between placebo and treatment arms. In addition, rehospitalisation rates and postoperative length of stay will be compared between the three groups.
Population:
150 adult patients undergoing ureteroscopy for ureteric stone disease stratified into negative ureteroscopy and those treated for a stone with or without stent insertion postoperatively Number of Sites: Tallaght Hospital Study Duration: 8 months
Detailed Description
Study Rationale Ureteroscopy is a widely performed procedure in urology. Pain is one of the commonest complications after ureteroscopy and one of the common reasons for re-admission after this procedure. Insertion of a stent post-ureteroscopy can cause pain affecting daily activities in 80% of the patients. Pain post ureteroscopy is multi-factorial and currently there is no specific method used clinically to treat this. Intraluminal injection of local anesthetic solution in the ureter has been extensively studied in the animal model with positive results. Intraluminal injection steroids has also been studied previously and steroids have also been used in medical expulsive therapy for ureteric stones previously. The investigators are proposing the use of high concentration alkalinized long-acting local anaesthetic levo-bupivicaine and long-acting steroid dexamethasone for post-ureteroscopy pain. It is simple, cheap, safe, easy to perform and widely available.
Background Intraluminal injection of local anesthetics (LA) in the ureter has been studied previously in animal models. Burdgya et al in 1986, USSR examined effects of LA on guinea pig ureters . Action potential of ureteric smooth muscle has initial fast component consisting of repeated gradually decaying spikes and a subsequent slow component i.e plateau. This action potential is accompanied by a brief contraction. Two opposite effects of LA occur on ureteric smooth muscle: Low concentrations of procaine, lignocaine and tetracaine (0.1-1 mM) at pH 7.4 increased duration of slow plateau of the evoked action potentials. At higher concentrations lignocaine (5mM) and tetracaine (0.5mM) caused complete inhibition of evoked action potentials and phasic contractions. Procaine 5mM predominantly inhibited contractile responses. High pH (9) significantly increased while low pH (pH 6) decreased the inhibitory action of procaine and lignocaine. Tetracaine had the most potent inhibitory action on ureter smooth muscle with the weakest stimulant action while lignocaine had stronger inhibitory effect on ureter smooth muscle than procaine. Ross et al in 1972 reported intraluminal injection of 2% lignocaine reduced peristaltic activity in 5 out of 15 ureters in their patients with no effect in the remaining group.
Andersson and Ulmsten found that local instillation of 4% lignocaine in their patients caused an initial brief stimulation followed by reduced activity. Tsuchida in 197 studied dog ureters to report prompt inhibitory effect of 4% lignocaine applied to mucosa invivo with no effect when applied to adventitia.
Struthers in 1976 in his invivo dog studies found both systemic and intraluminal administration of lignocaine, procaine and mepivacaine caused only hyperperistalsis and never inhibition. Sur et al published a study with intravesical injection of ropivacaine before ureteroscopic surgery demonstrated trends toward decreased pain and voiding symptoms. Patients received five injections of 2 mL 0.5% ropivacaine around the ureteral orifice or to the control cohort, who received five injections of 2 mL of 0.9% normal saline in identical locations. A pilot study suggested that PSD597 (intravesical alkalinized lidocaine) is effective for treating interstitial cystitis/painful bladder syndrome (IC/PBlS) , providing short-term amelioration of symptoms in a substantial proportion of patients, with a strong suggestion that repeating the treatment has a potentially cumulative effect. A randomized controlled trial comparing injection of non-irritating salt water (placebo), and half an injection of pH buffered lidocaine before the stent placement in patients undergoing ureteroscopy is currently being conducted. Till date there is no human study assessing the efficacy and safety of high concentration alkalinised long-acting LA injection for post-ureteroscopy pain based on the results of the animal studies outlined above.
The anaesthetic drug chosen for this study is levobupivacaine (Chirocaine™ -): it is S-isomer of bupivacaine, an amino-amide local anaesthetic widely used in regional anaesthesia, in postoperative analgesia and in treatment of acute and chronic pain. This drug produces sensory and motor nerve conduction block, acting on sodium channels of the cell membrane - sensitive to electric stimulus - but also on potassium and calcium channels. Moreover, it is remarkable for a rapid onset time and a long duration. In vitro and in vivo pharmacodynamic studies show that levobupivacaine has the same potency as bupivacaine, though the former is less likely to cause cardio- and neurotoxicity.
The effect of steroids on ureteric motility has previously been studied in in-vitro sheep models. Glucocorticoids inhibit the release of phospholipase A2 enzyme which catalyses the release of arachidonic acid from membrane phospholipids and thereby can have a spasmolytic action on the ureter by a prostaglandin-inhibitory action. Dexamethasone has shown the most potent dose dependant effect on the ureteral motility, it blocks ureteral motility in high concentrations within 24 minutes of instillation. Being a long-acting steroid, its duration of action in previous studies on nerve blocks and intra-articular injections is demonstrated at 12 weeks.
Study population: 150 patients undergoing ureteroscopy for ureteric stones:
Ureteric stone treatment (including proximal, mid and distal ureteric stones) with or without JJ stent insertion OR
Negative ureteroscopy (no stone found)
Pre and intraop: Obtain informed written consent pre-operatively with a pre-operative pain score, and rule out any allergies. Standardised uniform anesthetic regimen in all ureteroscopies.Post-ureteroscopy: drain the renal pelvis
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pain, Postoperative, Ureter Stone
Keywords
ureteroscopy, ureteric stent, intraluminal, local anaesthetic/anesthetic, steroid/glucocorticoid
7. Study Design
Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Three arm double-blinded prospective randomised controlled trial
Masking
ParticipantCare ProviderInvestigator
Masking Description
10 mls of solution will be handed to operating surgeon by the scrub nurse. The nurse will be the only person aware of the solution content and it will be documented discreetly. The operating surgeon, the investigator and the patients will not be aware of the solution used.
Allocation
Randomized
Enrollment
150 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Local anaesthetic
Arm Type
Active Comparator
Arm Description
Post-ureteroscopy intraluminal injection of alkalinised high concentration levo-bupivicaine in the renal pelvis
Arm Title
Local anaesthetic + steroid
Arm Type
Active Comparator
Arm Description
Post-ureteroscopy intraluminal injection of 10 mls alkalinised high concentration levo-bupivicaine with l dexamethasone in the renal pelvis
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Post-ureteroscopy intraluminal injection of 10 mls normal saline (placebo) in the renal pelvis
Intervention Type
Drug
Intervention Name(s)
Levobupivacaine
Intervention Description
intraluminal injection post procedure for pain relief: alkalinised high concentration 10 mls
Intervention Type
Drug
Intervention Name(s)
Dexamethasone Sodium Phosphate
Intervention Description
intraluminal injection post procedure for pain relief: alkalinised high concentration 10 mls levobupivicaine and 2mls dexamethasone
Intervention Type
Drug
Intervention Name(s)
Placebos
Intervention Description
10 mls normal saline
Primary Outcome Measure Information:
Title
Pain
Description
Visual Analog Pain Scale (VAS) at least 3 different time points post-ureteroscopy
Time Frame
at up to 7 days post op
Secondary Outcome Measure Information:
Title
Postoperative Nausea and Vomiting (PONV)
Time Frame
at up to 7 days post op
Title
Length of stay post-op
Time Frame
at up to 7 days post op
Title
rehospitalisation rate
Time Frame
at up to 7 days post op
Title
Need for analgesia
Time Frame
at up to 7 days post op
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Any patient undergoing ureteroscopy for ureteric stone disease
Able to undergo a general anaesthetic
At least 18 years old
Willing and able to complete patient symptom questionnaires
Exclusion Criteria:
Solitary Kidney
Renal failure
Anatomic bladder or ureteral abnormality
Uncorrected coagulopathy
Previous cystectomy or urinary diversion
Neurogenic bladder
Interstitial cystitis
Transplanted kidney
Pregnancy
Requires an indwelling catheter
Recurrent urinary tract infections
Pelvic kidney
Requires bilateral treatment/stents
Previous bladder or ureteral reconstructive surgery
Ureteral perforation during procedure
Known sensitivity to lidocaine
Febrile at time of randomization or treatment
Requires spinal anaesthetic
Stenting without stone treatment
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Nikita Bhatt
Phone
00353860609430
Email
nikitarb89@gmail.com
First Name & Middle Initial & Last Name or Official Title & Degree
Rustom Manecksha
Email
rustom.manecksha@gmail.com
Facility Information:
Facility Name
Adelaide and Meath incorporating National Children's hopsital
City
Dublin
ZIP/Postal Code
24
Country
Ireland
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Nikita R Bhatt
Phone
00353860609430
Email
nikitarb89@gmail.com
First Name & Middle Initial & Last Name & Degree
Rustom P Manecksha
Email
rustom.manecksha@gmail.com
First Name & Middle Initial & Last Name & Degree
Rustom P Manecksha, MD, FRCSI
First Name & Middle Initial & Last Name & Degree
Nikita R Bhatt, MRCS MCh
First Name & Middle Initial & Last Name & Degree
Gerard Fitzpatrick, MB FFARCSI FJFICMI
12. IPD Sharing Statement
Plan to Share IPD
Undecided
Citations:
PubMed Identifier
25431663
Citation
El Harrech Y, Abakka N, El Anzaoui J, Ghoundale O, Touiti D. Ureteral stenting after uncomplicated ureteroscopy for distal ureteral stones: a randomized, controlled trial. Minim Invasive Surg. 2014;2014:892890. doi: 10.1155/2014/892890. Epub 2014 Nov 9.
Results Reference
background
PubMed Identifier
3742148
Citation
Burdyga ThV, Magura IS. The effects of local anaesthetics on the electrical and mechanical activity of the guinea-pig ureter. Br J Pharmacol. 1986 Jul;88(3):523-30. doi: 10.1111/j.1476-5381.1986.tb10232.x.
Results Reference
background
Citation
Ross JA EP, Kirkland IS. Ibid. 1972:125.
Results Reference
background
PubMed Identifier
1209180
Citation
Andersson KE, Ulmsten U. Effects of spinal anaesthesia, lidocaine, and morphine, on the motility of the human ureter in vivo. Scand J Urol Nephrol. 1975;9(3):236-42. doi: 10.3109/00365597509134219.
Results Reference
background
Citation
Boyarsky ASaS. The Pharmacology of the Urinary Tract. In: Caine M, editor.1984.
Results Reference
background
PubMed Identifier
18290733
Citation
Sur RL, Haleblian GE, Cantor DA, Springhart WP, Albala DM, Preminger GM. Efficacy of intravesical ropivacaine injection on urinary symptoms following ureteral stenting: a randomized, controlled study. J Endourol. 2008 Mar;22(3):473-8. doi: 10.1089/end.2007.9847.
Results Reference
background
PubMed Identifier
19021619
Citation
Nickel JC, Moldwin R, Lee S, Davis EL, Henry RA, Wyllie MG. Intravesical alkalinized lidocaine (PSD597) offers sustained relief from symptoms of interstitial cystitis and painful bladder syndrome. BJU Int. 2009 Apr;103(7):910-8. doi: 10.1111/j.1464-410X.2008.08162.x. Epub 2008 Nov 13.
Results Reference
background
Citation
The American Heritage® Stedman's Medical Dictionary. http://www.dictionary.com/browse/life-expectancy. Accessed 13/12/16. 2002.
Results Reference
background
PubMed Identifier
2720291
Citation
Angelo-Khattar M, Thulesius O, Cherian T. The effect of glucocorticosteroids on in vitro motility of the ureter of the sheep. Br J Pharmacol. 1989 Mar;96(3):527-30. doi: 10.1111/j.1476-5381.1989.tb11849.x.
Results Reference
background
PubMed Identifier
17525777
Citation
Manchikanti L, Manchikanti KN, Manchukonda R, Cash KA, Damron KS, Pampati V, McManus CD. Evaluation of lumbar facet joint nerve blocks in the management of chronic low back pain: preliminary report of a randomized, double-blind controlled trial: clinical trial NCT00355914. Pain Physician. 2007 May;10(3):425-40.
Results Reference
background
Learn more about this trial
Local Anaesthetic and Steroid in the Ureter
We'll reach out to this number within 24 hrs